The Clinical and Hormonal Characteristics of Primary Adrenal Lymphomas: The Necessity of Early Detection of Adrenal Insufficiency

Published on Sep 1, 2017in Internal Medicine1.005
· DOI :10.2169/INTERNALMEDICINE.8216-16
Ko Harada3
Estimated H-index: 3
(Okayama University),
Kosuke Kimura5
Estimated H-index: 5
(Okayama University)
+ 6 AuthorsFumio Otsuka35
Estimated H-index: 35
(Okayama University)
: Objective To analyze the clinical and endocrine characteristics of patients with primary adrenal lymphoma. Patients We retrospectively reviewed the cases of five patients with primary adrenal lymphoma who were treated in our hospital between April 2004 and March 2015. We investigated the characteristics of the clinical and pathological findings, treatment, prognosis and complications of adrenal insufficiency. Results Adrenal insufficiency, which was confirmed by the laboratory data at the initial presentation, was observed in two cases. One case was complicated by relative adrenal insufficiency during a course of chemotherapy. The plasma adrenaline and urinary adrenaline levels were decreased in four cases and three cases, respectively. Diffusion MRI was radiologically diagnostic. In all of the cases, the patients were pathologically diagnosed with diffuse large-B cell lymphoma and were treated with rituximab and CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone)-like chemotherapy. Two patients received central nervous system prophylaxis with high-dose methotrexate. Four of the patients survived and one patient died during the follow-up period. Conclusion The early detection of adrenal insufficiency and the administration of an appropriate dose of hydrocortisone are necessary during the course of chemotherapy as well as at the initial manifestation. The exclusion of adrenal dysfunction prior to invasive diagnostic procedures, such as CT-guided needle biopsy, is also critical.
📖 Papers frequently viewed together
2 Citations
18 Citations
#1Toshihiko Yanase (Fukuoka University)H-Index: 58
#2Toshihiro TajimaH-Index: 29
Last. Soji KasayamaH-Index: 39
view all 17 authors...
: This clinical practice guideline of the diagnosis and treatment of adrenal insufficiency (AI) including adrenal crisis was produced on behalf of the Japan Endocrine Society. This evidence-based guideline was developed by a committee including all authors, and was reviewed by a subcommittee of the Japan Endocrine Society. The Japanese version has already been published, and the essential points have been summarized in this English language version. We recommend diagnostic tests, including measu...
37 CitationsSource
#1Troy Puar (Radboud University Nijmegen)H-Index: 7
#2Nike M. M. L. Stikkelbroeck (Radboud University Nijmegen)H-Index: 19
Last. Ad R. M. M. Hermus (Radboud University Nijmegen)H-Index: 61
view all 5 authors...
Adrenal crisis is a life-threatening medical emergency, associated with a high mortality unless it is appropriately recognized and early treatment is rendered. Despite it being a treatable condition for almost 70 years, failure of adequate preventive measures or delayed treatment has often led to unnecessary deaths. Gastrointestinal illness is the most common precipitant for an adrenal crisis. Although most patients are educated about "sick day rules," patients, and physicians too, are often rel...
77 CitationsSource
#1Chanyoon Cheah (University of Melbourne)H-Index: 1
#2Kirsten Herbert (University of Melbourne)H-Index: 14
Last. John F. Seymour (University of Melbourne)H-Index: 106
view all 20 authors...
A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma
63 CitationsSource
#1Satoshi Ichikawa (Tohoku University)H-Index: 22
#2Noriko Fukuhara (Tohoku University)H-Index: 16
Last. Hideo Harigae (Tohoku University)H-Index: 33
view all 14 authors...
Background Primary adrenal lymphoma (PAL) is an extremely rare subtype of extranodal non-Hodgkin’s lymphoma. Some researchers have reported some of the characteristics of PAL and its association with poor prognosis; however, the clinicopathological features of PAL remain to be elucidated.
17 CitationsSource
#1Armin Rashidi (EVMS: Eastern Virginia Medical School)H-Index: 29
#2Stephen I. FisherH-Index: 9
Fewer than 200 cases of primary adrenal lymphoma (PAL) have been reported. We have systematically reviewed all 187 cases of PAL reported in the English literature until June 2013, from which we drew the following conclusions: PAL is typically a highly symptomatic and aggressive, metabolically hyperactive, hypovascular, hypoechoic (and heterogeneous on ultrasound), hypodense (with slight to moderate enhancement on computed tomography), high-grade lymphoma, primarily affecting elderly males and pr...
94 CitationsSource
#1Yu Ri Kim (Yonsei University)H-Index: 13
#2Jin Seok Kim (Yonsei University)H-Index: 34
Last. Cheolwon Suh (UOU: University of Ulsan)H-Index: 34
view all 23 authors...
Background The objective of this study was to identify prognostic factors for survival in patients with primary diffuse large B-cell lymphoma (DLBCL) of the adrenal gland.
53 CitationsSource
#1Naoto Tomita (YCU: Yokohama City University)H-Index: 21
#2Masahiro YokoyamaH-Index: 19
Last. Kengo Takeuchi (JFCR: Japanese Foundation for Cancer Research)H-Index: 60
view all 25 authors...
Central nervous system (CNS) events, including CNS relapse and progression to CNS, are known to be serious complications in the clinical course of patients with lymphoma. This study aimed to evaluate the risk of CNS events in patients with diffuse large B-cell lymphoma in the rituximab era. We performed a retrospective survey of Japanese patients diagnosed with diffuse large B-cell lymphoma who underwent primary therapy with R-CHOP chemoimmunotherapy between September 2003 and December 2006. Pat...
64 CitationsSource
#1Robert Kridel (Geneva College)H-Index: 28
#2Pierre-Yves Dietrich (Geneva College)H-Index: 61
Summary CNS relapse occurs in about 5% of patients during the course of diffuse large B-cell lymphoma and entails a dismal prognosis. This consideration has led to the adoption of CNS prophylaxis, although known risk factors do not allow for an accurate prediction of CNS recurrences because they have insufficient sensitivity and specificity. Here, we review the reports of CNS events in major studies of diffuse large B-cell lymphoma before and after the introduction of rituximab, and probe the ev...
72 CitationsSource
#1Kana Miyazaki (Mie University)H-Index: 11
#2Motoko Yamaguchi (Mie University)H-Index: 32
Last. Shigeo Nakamura (Nagoya University)H-Index: 101
view all 20 authors...
(R-chemotherapy group; n = 184) or without (chemotherapy group; n = 153) rituximab. Results: No significant difference was found in clinical background comparisons between the two groups. In the R-chemotherapy group, 60% of the patients were older than 65 years at diagnosis. Both the complete response rate and overall survival (OS) were significantly better in the R-chemotherapy group (P = 0.0003 and P = 0.002, respectively). Multivariate analysis confirmed that chemotherapy without rituximab wa...
67 CitationsSource
#1Diego VillaH-Index: 30
#2Joseph M. ConnorsH-Index: 108
Last. Kerry J. SavageH-Index: 71
view all 5 authors...
Background Renal involvement is uncommon in diffuse large B-cell lymphoma. Recent data suggest that it is an independent risk factor for central nervous system relapse. We reviewed the clinical features, risk of central nervous system involvement, and survival of patients with diffuse large B-cell lymphoma with involvement of the kidney at diagnosis. Design and Methods All patients with diffuse large B-cell lymphoma and renal involvement diagnosed from January 1, 1982 to December 31, 2008 at the...
47 CitationsSource
Cited By3
#1Shamaila Zaman (Imperial College Healthcare)H-Index: 1
#2Hessa Boharoon (Imperial College Healthcare)H-Index: 1
Last. Karim Meeran (Imperial College Healthcare)H-Index: 12
view all 9 authors...
Abstract: Objective Dexamethasone is a known treatment for lymphoma, but it’s potency and rapidity of its effect has not been recognised. Our objective is to present a case of bilateral adrenal lymphoma, which significantly reduced in size after a single dose of dexamethasone. Methods Clinical course and investigations including Adrenocorticotropic hormone (ACTH), cortisol, short synacthen test, computed tomography (CT) and adrenal biopsy are presented. Results A 52-year-old man had a fall and w...
#1Claudia Rita CorsoH-Index: 10
#2Alexandra Acco (UFPR: Federal University of Paraná)H-Index: 19
Last. Lauro Mera de SouzaH-Index: 30
view all 6 authors...
Mitotane is the only adrenolytic drug approved by the FDA for treating adrenocortical carcinoma (ACC). This drug has cytotoxic effects on tumor tissues; it induces cell death and antisecretory effects on adrenal cells by inhibiting the synthesis of adrenocortical steroids, which are involved in the pathogenesis of ACC. However, high doses of mitotane are usually necessary to reach the therapeutic plasma concentration, which may result in several adverse effects. This suggests that important phar...
2 CitationsSource
#1Yan Wang (Sichuan University)H-Index: 1
#2Yan Ren (Sichuan University)H-Index: 9
Last. Tao Chen (Sichuan University)H-Index: 7
view all 8 authors...
Background and Objective: Primary adrenal lymphoma is a rare, progressive, easily misdiagnosed adrenal tumor with a poor prognosis. There are limited data on its clinical characteristics, and these have been derived from small sample studies. This study aimed to identify the clinical characteristics and prognosis of primary adrenal lymphoma. Methods: This single-center study retrospectively analyzed data of 50 primary adrenal lymphoma patients treated between January 2008 and January 2018. Demog...
1 CitationsSource